Hepatect Cp (Human Hepatitis B Immunoglobulin)

Hepatect Cp is indicated for several clinical situations where passive immunity against hepatitis B virus is required.

• Post‑exposure prophylaxis for individuals who have been exposed to hepatitis B virus.
• Prevention of hepatitis B recurrence in patients undergoing liver transplantation.
• Prophylaxis of hepatitis B infection in newborns born to HBsAg‑positive mothers.
• Supplementation of hepatitis B immunity in patients with inadequate vaccine response.
• Use in combination with hepatitis B vaccine for enhanced protection in high‑risk populations.

Adverse reactions to Hepatect Cp are generally related to the intravenous administration of human immunoglobulin and may vary in frequency and severity.

Common

• Mild fever or chills during or shortly after infusion.
• Headache or fatigue.
• Nausea, vomiting, or abdominal discomfort.
• Localized infusion site reactions such as erythema or swelling.
• Transient hypotension or dizziness.

Serious

• Allergic reactions including urticaria, angioedema, or anaphylaxis.
• Acute hemolytic transfusion reactions.
• Renal impairment or acute kidney injury.
• Thrombotic events such as deep vein thrombosis.

When prescribing Hepatect Cp, clinicians should consider patient-specific factors and follow safety guidelines to minimize risks associated with immunoglobulin therapy.

• Assess for known hypersensitivity to human immunoglobulin or any product components.
• Evaluate renal function before infusion, especially in patients with pre‑existing kidney disease.
• Monitor for signs of hemolysis in individuals with blood group incompatibilities.
• Use caution in patients with a history of thromboembolic disorders.
• Avoid rapid infusion rates; adhere to recommended administration speed.
• Consider pregnancy status; data are limited, and benefits should outweigh potential risks.

Hepatect Cp may interact with other medications or clinical conditions; awareness of potential interactions helps ensure safe administration.

Avoid

• Concurrent use of other blood products containing anti‑HBs antibodies without medical justification.
• Administration with live vaccines during the same visit, as passive antibodies may reduce vaccine efficacy.

Use with caution

• Concomitant anticoagulants or antiplatelet agents, due to possible increased bleeding risk.
• Immunosuppressive therapies, which may alter the immunogenic response.
• Renal‑impairing drugs, requiring close monitoring of kidney function.
• High‑dose steroids, which could affect infusion tolerance.